tobradex 1+3 mg/ml øjendråber, suspension
orifarm a/s - dexamethason, tobramycin - øjendråber, suspension - 1+3 mg/ml
tobradex 1+3 mg/ml øjendråber, suspension
paranova danmark a/s - dexamethason, tobramycin - øjendråber, suspension - 1+3 mg/ml
oridecin 1+3 mg/ml øjendråber, suspension
orifarm generics a/s - dexamethason, tobramycin - øjendråber, suspension - 1+3 mg/ml
pirimor 500 wg vanddispergerbart granulat
adama northern europe b.v. - pirimicarb - vanddispergerbart granulat - 500 g/kg pirimicarb
champix
pfizer europe ma eeig - vareniclin - anvendelse af tobaksbrug - andre narkotika stoffer - champix er indiceret til rygestop hos voksne.
palladia
zoetis belgium sa - toceranib - antineoplastiske midler - hunde - behandling af ikke-resekterbare patnaik grade ii (mellemklasse) eller -iii (højkvalitets), tilbagevendende, kutane mastcelletumorer hos hunde.
trocoxil
zoetis belgium sa - mavacoxib - anti inflammatorisk, og antireumatiske produkter - hunde - til behandling af smerte og betændelse forbundet med degenerativ leddssygdom hos hunde i tilfælde hvor kontinuerlig behandling på mere end en måned er angivet.
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.